137 related articles for article (PubMed ID: 11215326)
1. General pharmacology of IY-81149, a new proton pump inhibitor.
Kim EJ; Lee RK; Lee SM; Kim DY
Arzneimittelforschung; 2001 Jan; 51(1):51-9. PubMed ID: 11215326
[TBL] [Abstract][Full Text] [Related]
2. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
3. General pharmacological properties of YJA 20379-1, a novel proton pump inhibitor with antiulcer activities.
Lee EB; Cho SI; Cheon SA; Chang MS; Kim KB; Sohn SK; Chung YK
Arzneimittelforschung; 1999 Dec; 49(12):1018-24. PubMed ID: 10635448
[TBL] [Abstract][Full Text] [Related]
4. Safety pharmacology of CKD-602, a novel anticancer agent.
Kim EJ; Lee RK; Suh JE; Han SS; Kim JK
Arzneimittelforschung; 2003; 53(4):272-9. PubMed ID: 12785124
[TBL] [Abstract][Full Text] [Related]
5. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
Kito G; Morimoto S; Shiomi M
Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
[TBL] [Abstract][Full Text] [Related]
6. General pharmacology of the new antiviral agent SK 1899.
Ryu KH; Rhee HI; Jung I; Kim TS; Lee SJ; Im GJ; Lee N; Ryu DH; Kim YW; Kim JJ; Chang K; Lee BH; Shin HS; Kim EJ; Kim KH; Kim DK
Arzneimittelforschung; 2000 Apr; 50(4):395-403. PubMed ID: 10800640
[TBL] [Abstract][Full Text] [Related]
7. General pharmacology of the new antimuscarinic compound vamicamide.
Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
[TBL] [Abstract][Full Text] [Related]
8. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
[TBL] [Abstract][Full Text] [Related]
9. General pharmacological properties of YJA20379-8, a new H+/K(+)-ATPase inhibitor with anti-ulcer activities.
Lee EB; Cho SI; Chang HO; Chang MS; Kim KB; Lee SB; Choi WS
Arzneimittelforschung; 2001; 51(8):659-66. PubMed ID: 11556127
[TBL] [Abstract][Full Text] [Related]
10. General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol.
Hirohashi M; Takasuna K; Tamura K; Yamaguchi K; Maekawa K; Yamada S; Iwasaki S; Yoshida M; Nomura M; Taguchi K
Arzneimittelforschung; 1990 Jul; 40(7):735-46. PubMed ID: 1977393
[TBL] [Abstract][Full Text] [Related]
11. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
[TBL] [Abstract][Full Text] [Related]
12. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
[TBL] [Abstract][Full Text] [Related]
13. General pharmacological properties of the new vasodilator flosequinan.
Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
[TBL] [Abstract][Full Text] [Related]
14. General pharmacological profile of the new anti-ulcer drug 3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl]methyl]-amino-N -methylbenzamide.
Hirohashi M; Takasuna K; Kasai Y; Usui C; Tamura K; Kojima H
Arzneimittelforschung; 1993 May; 43(5):569-77. PubMed ID: 8329002
[TBL] [Abstract][Full Text] [Related]
15. General pharmacology of the new non-xanthine adenosine A1 receptor antagonist (+)-(R)-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2- piperidine ethanol.
Terai T; Kusunoki T; Kita Y; Yoshida K; Akahane A; Shiokawa Y; Kohno Y; Horiai H; Mori J; Mine Y; Kohsaka M
Arzneimittelforschung; 1996 Feb; 46(2):185-91. PubMed ID: 8720311
[TBL] [Abstract][Full Text] [Related]
16. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects.
Murata T; Murai T; Kanai T; Ogaki Y; Sanai K; Kanda H; Sato S; Kajikawa N; Umetsu T; Matsuura H
Arzneimittelforschung; 1989 Aug; 39(8):867-76. PubMed ID: 2510743
[TBL] [Abstract][Full Text] [Related]
17. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.
Furuta S; Shimada O; Doi N; Ukai K; Nakagawa T; Watanabe J; Imaizumi M
Arzneimittelforschung; 2004; 54(12):868-80. PubMed ID: 15646371
[TBL] [Abstract][Full Text] [Related]
18. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3- dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals.
Algate DR; Augustin J; Atterson PR; Beard DJ; Jobling CM; Laufer S; Munt PL; Tries S
Arzneimittelforschung; 1995 Feb; 45(2):159-65. PubMed ID: 7710439
[TBL] [Abstract][Full Text] [Related]
19. General pharmacology of recombinant human basic fibroblast growth factor.
Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
[TBL] [Abstract][Full Text] [Related]
20. General pharmacological properties of the main metabolite of flosequinan.
Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
